Assessment of Patient Attitudes About Mometasone Furoate Nasal Spray: The Ease-of-Use Patient Survey

World Allergy Organization Journal

April M Dowdee¹  Gabriel R Ortiz²  Leonard M Fromer³ 

[1] Phadia US Inc, Portage, MI;Allergy and Asthma Center of El Paso, El Paso, TX;University of California, Los Angeles School of Medicine, Los Angeles, CA

关键词: allergic rhinitis;    survey;    mometasone furoate;    ease of use;   

Others  :  824482
DOI  :  10.1097/WOX.0b013e3181865f99

 received in 2008-01-29, accepted in 2008-07-10,  发布年份 2008

【 摘 要 】

Background

Intranasal corticosteroids (INS) are recommended as first-line therapy for allergic rhinitis. To date, no studies have evaluated the impact of an INS delivery system on patient satisfaction. Unless patients use a medication appropriately and consistently, they will not fully benefit from its therapeutic effects.

Objective

To determine whether the characteristics of the mometasone furoate nasal spray (MFNS) delivery device are an impediment to its use.

Methods/Database

A random sample of preidentified MFNS users was recruited through e-mail (N = 1544). In online interviews, participants were asked about MFNS ease of use and attributes.

Results

Ninety-eight percent of respondents reported that MFNS is easy to use, and 96% said that the applicator is easy to administer. Nearly all elderly users and users with arthritis said that the applicator fits comfortably in the nostril (96% and 97%, respectively) and is appropriately sized (97% and 96%, respectively); 96% of pediatric users agreed that the applicator fits comfortably. All users said the applicator's ease of use and comfortable fit were its most important attributes.

Conclusions

The perceived ease of use of MFNS may help providers appropriately treat patients with allergic rhinitis and may improve patient adherence to INS use.

【 授权许可】

   
2008 World Allergy Organization; licensee BioMed Central Ltd.

【 参考文献 】

• [1]American Academy of Allergy Asthma & Immunology: The allergy report, volume I: overview of allergic diseases: diagnosis, management, and barriers to care. Milwaukee, WI: AAAAI; 2000.
• [2]Fireman P: Allergic rhinitis. In Atlas of Allergies. Edited by Fireman P, Slavin RG. Philadelphia, PA: JB Lippincott; 1991:9.2-9.18.
• [3]McMenamin P: Costs of hay fever in the United States in 1990. Ann Allergy 1994, 7:35-39.
• [4]Centers for Disease Control and Prevention: National Center for Health Statistics: National Ambulatory Medical Care Survey: 2004 summary. [http://www.cdc.gov/nchs/data/ad/ad374.pdf] webcite Accessed August 11, 2008
• [5]Rossoff LJ, Stempel DA, Alam R: The health and economic impact of rhinitis. Am J Manag Care 1997, 3(Suppl):S8-S18.
• [6]Santos R, Cifaldi M, Gregory C, Seitz P: Economic outcomes of a targeted intervention program: the costs of treating allergic rhinitis patients. Am J Manag Care 1999, 5(Suppl):S225-S234.
• [7]Kay GG: The effects of antihistamines on cognition and performance. J Allergy Clin Immunol 2000, 105:S622-S627.
• [8]The UCB Institute of Allergy: European Allergy White Paper. Chapter 5: Socio-economic costs of allergic diseases. Brussels, Belgium: UCB; 1997.
• [9]Bousquet J, Bullinger M, Fayol C, Marquis P, Valentin B, Burtin B: Assessment of quality of life in patients with perennial allergic rhinitis with the French version of the SF-36 Health Status Questionnaire. J Allergy Clin Immunol 1994, 94:182-188.
• [10]Thompson AK, Juniper E, Meltzer EO: Quality of life in patients with allergic rhinitis. Ann Allergy Asthma Immunol 2000, 85:338-348.
• [11]Malone CD, Lawson KA, Smith DH, et al.: A cost of illness study of allergic rhinitis in the United States. J Allergy Clin Immunol 1997, 99:22-27.
• [12]Spector SL: Overview of comorbid associations of allergic rhinitis. J Allergy Clin Immunol 1997, 99:S773-S780.
• [13]Settipane R: Complications of allergic rhinitis. Allergy Asthma Proc 1999, 20:209-213.
• [14]Meltzer EO, Bardelas J, Goldsobel A, Kaiser H: A preference evaluation study comparing the sensory attributes of mometasone furoate and fluticasone propionate nasal sprays by patients with allergic rhinitis. Treat Respir Med 2005, 4:289-296.
• [15]Kirmaz C, Aydemir O, Bayrak P, Yuksel H, Ozenturk O, Degirmenci S: Sexual dysfunction in patients with allergic rhinoconjunctivitis. Ann Allergy Asthma Immunol 1999, 95:525-529.
• [16]Dykewicz MS, Fineman S: Executive summary of Joint Task Force Practice Parameters on Diagnosis and Management of Rhinitis. Ann Allergy Asthma Immunol 1998, 81:463-468.
• [17]Lamb CE, Ratner PH, Johnson CE, Ambegaonkar AJ, Joshi AV, Day D, et al.: Economic impact of workplace productivity losses due to allergic rhinitis compared with select medical conditions in the United States from an employer perspective. Curr Med Res Opin 2006, 22:1203-1210.
• [18]Bousquet J, van Cauwenberge P, Khaltaev N: ARIAWorkshop Group, World Health Organization. Allergic rhinitis and its impact on asthma. J Allergy Clin Immunol 2001, 108(Suppl):S147-S334.
• [19]van Cauwenberge P, Bachert C, Passalacqua G, Bousquet J, Canonica GW, Durham SR, et al.: Consensus statement on the treatment of allergic rhinitis. Allergy 2000, 55:116-134.
• [20]Mygind N: Glucocorticosteroids and rhinitis. Allergy 1993, 48:476-490.
• [21]Bachert C, El-Akkad T: Patient preferences and sensory comparisons of three intranasal corticosteroids for the treatment of allergic rhinitis. Ann Allergy Asthma Immunol 2002, 89:292-297.
• [22]Storms WW: Introduction: patient preference of inhaled nasal corticosteroids. Allergy Asthma Proc 2001, 22(Suppl 1):S1-S3.
• [23]Blaiss MS: Efficacy, safety, and patient preference of inhaled nasal corticosteroids: a review of pertinent published data. Allergy Asthma Proc 2001, 22(Suppl 1):S5-S10.
• [24]Stokes M, Amorosi SL, Thompson D, Dupclay L, Garcia J, Georges G: Evaluation of patients' preferences for triamcinolone acetonide aqueous, fluticasone propionate, and mometasone furoate nasal sprays in patients with allergic rhinitis. Otolaryngol Head Neck Surg 2004, 131:225-231.
• [25]Khanna P, Shah A: Assessment of sensory perceptions and patient preference for intranasal corticosteroid sprays in allergic rhinitis. Am J Rhinol 2005, 19:316-321.
• [26]Nasonex (mometasone furoate nasal spray) [prescribing information] Kenilworth, NJ: Schering Corporation; 2005.
• [27]Roper Public Affairs & Media Group of NOP World: Impact of nasal congestion among allergic rhinitis sufferers. 2004.
• [28]Dupclay L, Doyle J: Assessment of intranasal corticosteroid use in allergic rhinitis: benefits, costs, and patient preferences. Am J Manag Care 2002, 8(Suppl):S335-S340.